Atea Pharmaceuticals (AVIR) Net Cash Flow (2020 - 2022)
Historic Net Cash Flow for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $11.9 million.
- Atea Pharmaceuticals' Net Cash Flow rose 11586.46% to $11.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$576.0 million, marking a year-over-year decrease of 57339.49%. This contributed to the annual value of -$79.1 million for FY2024, which is 7648.49% down from last year.
- Atea Pharmaceuticals' Net Cash Flow amounted to $11.9 million in Q4 2022, which was up 11586.46% from -$508.1 million recorded in Q3 2022.
- Atea Pharmaceuticals' Net Cash Flow's 5-year high stood at $744.7 million during Q4 2020, with a 5-year trough of -$508.1 million in Q3 2022.
- Moreover, its 3-year median value for Net Cash Flow was -$13.4 million (2020), whereas its average is $13.9 million.
- As far as peak fluctuations go, Atea Pharmaceuticals' Net Cash Flow skyrocketed by 32478.62% in 2021, and later tumbled by 227142.49% in 2022.
- Atea Pharmaceuticals' Net Cash Flow (Quarter) stood at $744.7 million in 2020, then crashed by 110.11% to -$75.3 million in 2021, then skyrocketed by 115.86% to $11.9 million in 2022.
- Its Net Cash Flow was $11.9 million in Q4 2022, compared to -$508.1 million in Q3 2022 and -$21.1 million in Q2 2022.